POM: Prescription only medicine
Short description of latest update of the Keytruda Materials
The risk minimisation materials for pembrolizumab were developed as a condition of the marketing authorisation grant for this product. The patient alert card should be issued to and carried by patients being treated with pembrolizumab and provides important safety information to minimise the risk of immune-related adverse reactions. In addition it contains emergency contact details for the patient and their specialist,
The risk minimisation materials for pembrolizumab were developed as a condition of the Marketing Authorisation grant for this product. This brochure is for patients and will explain some of the side effects that might occur during or after treatment with pembrolizumab, and how to check for them.